A. Michael Lincoff, MD, FACC

General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Novo Nordisk(SIGNIFICANT), Eli Lilly and Company(SIGNIFICANT), Novartis(SIGNIFICANT), Becton Dickson(SIGNIFICANT), Fibrogen(NONE), Provention(NONE), Endologix(NONE), Akebia(NONE) RESEARCH/RESEARCH GRANTS: Edwards Lifesciences(SIGNIFICANT), Medtronic(SIGNIFICANT), Amgen(SIGNIFICANT), CSL Behring(SIGNIFICANT), Janssen(SIGNIFICANT), Lilly(SIGNIFICANT), Pfizer(SIGNIFICANT), Ethicon(SIGNIFICANT), Infraredx(SIGNIFICANT), AbbVie, Inc.(SIGNIFICANT), Astra Zeneca(SIGNIFICANT), Esperion(SIGNIFICANT), Cardiac Dimensions(SIGNIFICANT), Boston Scientific(SIGNIFICANT), Gilead Sciences, Inc. (SIGNIFICANT), Genentech, Inc(SIGNIFICANT), Kiniksa(SIGNIFICANT), Novartis(SIGNIFICANT)

View Full Disclosure